Hepalink
6
29M
5
0.26
0.17
3
- Areas of investment
Summary
In 1998 was created Hepalink, which is appeared as Corporate Investor. The venture was found in Asia in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Hepalink, startups are often financed by Wellcome Trust, TVM Capital, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Woodford Investment Management, Wellcome Trust, TVM Capital. In the next rounds fund is usually obtained by Xeraya Capital, Bill & Melinda Gates Foundation, Bain Capital Life Sciences.
Considering the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2015.
The fund has specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Rapid Micro Biosystems, OncoQuest. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - Canada.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 0
- Exits
- 3
- Rounds per year
- 0.26
- Follow on index
- 0.17
- Investments by industry
- Biotechnology (5)
- Biopharma (4)
- Health Care (3)
- Therapeutics (2)
- Drug Discovery (1) Show 5 more
- Investments by region
-
- United Kingdom (1)
- China (1)
- United States (1)
- Canada (3)
- Peak activity year
- 2015
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Avg. valuation at time of investment
- 220M
- Group Appearance index
- 0.50
- Avg. company exit year
- 11
- Avg. multiplicator
- 4.80
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Rapid Micro Biosystems | 29 Apr 2015 | Biotechnology, Manufacturing, Pharmaceutical | Late Stage Venture | 25M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.